Siemens (NYSE:SI) Healthineers and HeartFlow said yesterday they inked a global collaborative deal to develop a solution for diagnosing and managing patients with suspected coronary artery disease.

The collaborative deal will join CT Scanners from Siemens Healthineers with HeartFlow’s FFRct Analysis fractional flow reserve software to create personalized 3D models of each patients’ arteries while computer algorithms simulate blood flow and look for arterial blockages.

“It is a fact that the treatment planning for coronary artery disease patients can be improved via quantitative data out of FFR measurements. With our exciting partnership between Siemens Healthineers and HeartFlow, Inc., we create an integrated solution that combines the exceptional cCTA images acquired by our high performance scanners with the only commercial product available that can derive FFR analysis noninvasively from CT data,” Siemens Healthineers computed tomography head André Hartung said in a press release.

The companies said that the combined clinical pathway of CT angiography and HeartFlow’s FFRct analysis can yield actionable information to help determine the patient’s optimal course of treatment.

“HeartFlow is pleased to collaborate with Siemens Healthineers, with its outstanding technology, tremendous expertise, and global reach Like HeartFlow, Siemens Healthineers is deeply committed to helping clinicians improve the patient experience and clinical outcomes while also helping them to reduce the total cost of healthcare. By working together, we can ensure this technology gets to every patient who can benefit from it,” CEO Dr. John Stevens said in a prepared statement.

The collaboration will focus initially on the US, with plans to expand into additional markets in the future.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW